Literature DB >> 25645920

Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.

Murugabaskar Balan1, Eduardo Mier y Teran2, Ana Maria Waaga-Gasser3, Martin Gasser3, Toni K Choueiri4, Gordon Freeman4, Soumitro Pal5.   

Abstract

The receptor tyrosine kinase c-Met is overexpressed in renal cancer cells and can play major role in the growth and survival of tumor. We investigated how the c-Met-mediated signaling through binding to its ligand hepatocyte growth factor (HGF) can modulate the apoptosis and immune escape mechanism(s) of renal cancer cells by the regulations of novel molecules heme oxygenase-1 (HO-1) and programmed death-1 ligand 1 (PD-L1). We found that HGF/c-Met-mediated signaling activated the Ras/Raf pathway and down-regulated cancer cell apoptosis; and it was associated with the overexpression of cytoprotective HO-1 and anti-apoptotic Bcl-2/Bcl-xL. c-Met-induced HO-1 overexpression was regulated at the transcriptional level. Next, we observed that c-Met induction markedly up-regulated the expression of the negative co-stimulatory molecule PD-L1, and this can be prevented following treatment of the cells with pharmacological inhibitors of c-Met. Interestingly, HGF/c-Met-mediated signaling could not induce PD-L1 at the optimum level when either Ras or HO-1 was knocked down. To study the functional significance of c-Met-induced PD-L1 expression, we performed a co-culture assay using mouse splenocytes (expressing PD-L1 receptor PD-1) and murine renal cancer cells (RENCA, expressing high PD-L1). We observed that the splenocyte-mediated apoptosis of cancer cells during co-culture was markedly increased in the presence of either c-Met inhibitor or PD-L1 neutralizing antibody. Finally, we found that both c-Met and PD-L1 are significantly up-regulated and co-localized in human renal cancer tissues. Together, our study suggests a novel mechanism(s) by which c-Met can promote increased survival of renal cancer cells through the regulation of HO-1 and PD-L1.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  PD-L1; Ras protein; apoptosis; c-Met; cancer; heme oxygenase; hepatocyte growth factor/scatter factor (HGF/SF); renal cancer; signal transduction

Mesh:

Substances:

Year:  2015        PMID: 25645920      PMCID: PMC4375468          DOI: 10.1074/jbc.M114.612689

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α.

Authors:  Tae-Hyoung Kim; Eu-gene Hur; Su-Jin Kang; Jung-Ae Kim; Dinesh Thapa; You Mie Lee; Sae Kwang Ku; Yunjin Jung; Mi-Kyoung Kwak
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

2.  Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation.

Authors:  Angelo A Chora; Paulo Fontoura; Andreia Cunha; Teresa F Pais; Sílvia Cardoso; Peggy P Ho; Lowen Y Lee; Raymond A Sobel; Lawrence Steinman; Miguel P Soares
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

3.  Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.

Authors:  Dipak Datta; Jesse A Flaxenburg; Sreenivas Laxmanan; Christopher Geehan; Martin Grimm; Ana Maria Waaga-Gasser; David M Briscoe; Soumitro Pal
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

4.  The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity.

Authors:  Jea-Hyun Baek; Carmen Birchmeier; Martin Zenke; Thomas Hieronymus
Journal:  J Immunol       Date:  2012-07-16       Impact factor: 5.422

5.  Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma.

Authors:  Yasuyoshi Miyata; Hiroshi Kanetake; Shigeru Kanda
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

6.  Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Authors:  F Michael Yakes; Jason Chen; Jenny Tan; Kyoko Yamaguchi; Yongchang Shi; Peiwen Yu; Fawn Qian; Felix Chu; Frauke Bentzien; Belinda Cancilla; Jessica Orf; Andrew You; A Douglas Laird; Stefan Engst; Lillian Lee; Justin Lesch; Yu-Chien Chou; Alison H Joly
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

7.  Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.

Authors:  Shari Pilon-Thomas; Amy Mackay; Nasreen Vohra; James J Mulé
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

8.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

9.  Coupling Met to specific pathways results in distinct developmental outcomes.

Authors:  F Maina; G Panté; F Helmbacher; R Andres; A Porthin; A M Davies; C Ponzetto; R Klein
Journal:  Mol Cell       Date:  2001-06       Impact factor: 17.970

10.  Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production.

Authors:  Sotiria Tzima; Panayiotis Victoratos; Ksanthi Kranidioti; Maria Alexiou; George Kollias
Journal:  J Exp Med       Date:  2009-04-27       Impact factor: 14.307

View more
  60 in total

1.  Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.

Authors:  Mathias Fiedler; Florian Weber; Matthias G Hautmann; Frank Haubner; Torsten E Reichert; Christoph Klingelhöffer; Stephan Schreml; Johannes K Meier; Arndt Hartmann; Tobias Ettl
Journal:  Clin Oral Investig       Date:  2017-03-18       Impact factor: 3.573

Review 2.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.

Authors:  Kabir A Khan; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

3.  Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.

Authors:  Sushil Kumar; Viralkumar Davra; Alison E Obr; Ke Geng; Teresa L Wood; Mariana S De Lorenzo; Raymond B Birge
Journal:  Oncoimmunology       Date:  2017-09-27       Impact factor: 8.110

4.  The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma.

Authors:  Jun Kajihara; Yoshito Tomimaru; Hidetoshi Eguchi; Daisaku Yamada; Hiroshi Wada; Akira Tomokuni; Tadafumi Asaoka; Koichi Kawamoto; Shigeru Marubashi; Hiroaki Nagano; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

5.  MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1.

Authors:  Cheng-Gang Li; Meng-Fan Pu; Chun-Zhu Li; Man Gao; Ming-Xia Liu; Cun-Zhi Yu; Hong Yan; Chun Peng; Yang Zhao; Yu Li; Ze-Long Ma; Xin-Ming Qi; Yi-Zheng Wang; Ling-Ling Miao; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2016-09-19       Impact factor: 6.150

6.  Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma.

Authors:  Xian Sun; Chia-Wei Li; Wei-Jan Wang; Mei-Kuang Chen; Hui Li; Yun-Ju Lai; Jennifer L Hsu; Paul B Koller; Li-Chuan Chan; Pei-Chih Lee; Fang-Ju Cheng; Clinton Yam; Gong-Yan Chen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

7.  Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.

Authors:  Sinéad A Noonan; Lynne Berry; Xian Lu; Dexiang Gao; Anna E Barón; Patrick Chesnut; Jamie Sheren; Dara L Aisner; Dan Merrick; Robert C Doebele; Marileila Varella-Garcia; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2016-06-01       Impact factor: 15.609

Review 8.  Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment.

Authors:  Tonglei Fang; Junyuan Xiao; Yiran Zhang; Haiyan Hu; Yueqi Zhu; Yingsheng Cheng
Journal:  Quant Imaging Med Surg       Date:  2021-06

Review 9.  HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.

Authors:  Stefan Hartmann; Neil E Bhola; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2016-07-01       Impact factor: 12.531

10.  Mammary Tumor Cells with High Metastatic Potential Are Hypersensitive to Macrophage-Derived HGF.

Authors:  Takanori Kitamura; Yu Kato; Demi Brownlie; Daniel Y H Soong; Gaël Sugano; Nicolle Kippen; Jiufeng Li; Dahlia Doughty-Shenton; Neil Carragher; Jeffrey W Pollard
Journal:  Cancer Immunol Res       Date:  2019-10-15       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.